Cas:50789-45-2 3-Phenoxybenzonitrile manufacturer & supplier

We serve Chemical Name:3-Phenoxybenzonitrile CAS:50789-45-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

3-Phenoxybenzonitrile

Chemical Name:3-Phenoxybenzonitrile
CAS.NO:50789-45-2
Synonyms:3-phenoxybenzonitrile
Molecular Formula:C13H9NO
Molecular Weight:195.21700
HS Code:2926909090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:149ºC
Density:1.17g/cm3
Index of Refraction:1.61
PSA:33.02000
Exact Mass:195.06800
LogP:3.35058

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 3-phenoxybenzonitrile chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-phenoxybenzonitrile physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-phenoxybenzonitrile Use and application,3-phenoxybenzonitrile technical grade,usp/ep/jp grade.


Related News: The vaccine also proved safe during the two-year trial, in which eleven doses were administered to randomly chosen patients with mild dementia. People who received the vaccine, known as AADvac1, experienced about the same numbers of side effects and adverse events as those who were given a placebo. 3-Phenoxybenzonitrile manufacturer Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS. 3-Phenoxybenzonitrile supplier “They will now look to re-engage with the FDA to better understand the bar donanemab needs to clear to potentially obtain a more expedited regulatory approval.” 3-Phenoxybenzonitrile vendor Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS. 3-Phenoxybenzonitrile factory The vaccine also proved safe during the two-year trial, in which eleven doses were administered to randomly chosen patients with mild dementia. People who received the vaccine, known as AADvac1, experienced about the same numbers of side effects and adverse events as those who were given a placebo.